(Q47904800)

6 February 2018

title

The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes. (English)

1 reference

6 February 2018

0 references

0 references

Bregenholt S

1

1 reference

6 February 2018

Wang M

2

1 reference

6 February 2018

Wolfe T

3

1 reference

6 February 2018

Hughes A

4

1 reference

6 February 2018

Baerentzen L

5

1 reference

6 February 2018

Dyrberg T

6

1 reference

6 February 2018

von Herrath MG

7

1 reference

6 February 2018

Petersen JS

8

1 reference

6 February 2018

publication date

1 May 2003

1 reference

6 February 2018

Scandinavian Journal of Immunology

published in

1 reference

6 February 2018

volume

57

1 reference

6 February 2018

issue

5

1 reference

6 February 2018

page(s)

432-438

1 reference

6 February 2018

Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

The initiation of autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Insulin-dependent diabetes mellitus and its animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: its relevance for treatment in established diabetes and islet transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Immune responses to dietary antigens: oral tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Oral tolerance in the treatment of inflammatory autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Induction of tolerance in macrophages by cholera toxin B chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01248.X

10.1046/J.1365-3083.2003.01248.X

21 January 2018

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

12753499

1 reference

6 February 2018